RE:RE:Juvente + Scientific claims validated in a trial = BIG $The carrying costs of Juvente do seem pretty steep for the current return but I think a high quality, premium cream with Oat BG, AV and CBD could realy find a market and at a premium price. Topical cannabis creams at the OCS range from $40 to $100 without the added benefits of AV and oat BG. Still just potential at this point with Juvente but hopefully some develpoments soon.
Ciao wrote: Oat BG could penetrate deep into the dermis and adding AV was another advantage for a cosmeceutical. These has been incorporated into some of the Juvente skin care products. Without marketing ($$$) and customer acceptance of fhis product, sales last year amounted to $27K and $30K the year before.
Until they find a partner who wants to place bioactives into a product, they should literally leave Juvente on the shelf. They are paying a GM (who sold them Juvente) a salary to look after a line of products that sold $27K worth of product last year and a subsidiary that lost $340K.
When you hear that they will allocate research dollars to their pipeline strategically to preserve capital, one realizes that $340K goes a long way.
prophetoffacts wrote: With Juvente CZO has demonstrated that it can create an award winning consumer product. Gilles said that it isn't CZO's intention to compete in marketing. CZO's intention is to use Juvente as a delivery platform for unique PGX. Imagine a prescription product:
Juvente +
Proprietary PGX impregnated biopolymers +
Scientific claims validated in a clinical trial
GOLDEN GILLES
Also, imagine a second-generation product that delivered high concentration avenanthramide deeply into the skin with PGX. Second Generation Aveeno?